

Oncotest GmbH

[View the current Oncotest GmbH Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocomplete/7815-Oncotest+GmbH.html>)

Contact Details:

Am Flughafen 8-10
Freiburg
Baden-Württemberg
D-79110
Germany

Tel: 49 761 51559 0

Fax: 49 761 51559 55

Email:

Recent Publications by Oncotest GmbH:



- [Mansouramycins A-D, Cytotoxic Isoquinolinequinones from a Marine Streptomyces \(1\).](#)
Chemical screening of the ethyl acetate extract from the marine-derived...20th November, 2009
Institute of Organic and Biomolecular Chemistry, University of Gottingen,- J Nat Prod. 2009 Nov 18. ([DOI Direct Link](#))
- [Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents.](#)
As new target-directed anticancer agents emerge, preclinical efficacy...7th February, 2009
Institute for Experimental Oncology, Oncotest GmbH, Freiburg, Germany.- Cancer Genomics Proteomics. 2008 Sep-Oct;5(5):263-73.
- [Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention.](#)
Approximately 50% of all cancer patients develop cachexia, a...6th December, 2007
Institute for Experimental Oncology, Oncotest GmbH, Am Flughafen 12-14,- Cancer Genomics Proteomics. 2007 May-Jun;4(3):223-31.
- [Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.](#)
Patient tumor explants established subcutaneously in serial passage in...6th December, 2007
Oncotest GmbH, Institute for Experimental Oncology, Am Flughafen 12-14,- Cancer Genomics Proteomics. 2007 May-Jun;4(3):197-209.
- [Gene signature-based prediction of tumor response to cyclophosphamide.](#)
Cyclophosphamide (CY) is a clinically used cytotoxic agent that is...6th December, 2007

Oncotest GmbH, Institute for Experimental Oncology, Am Flughafen 12-14,- Cancer Genomics Proteomics. 2007 May-Jun;4(3):187-95.

- [Microarrays of 41 human tumor cell lines for the characterization of new molecular targets: expression patterns of cathepsin B and the transferrin receptor.](#)
*In recent years the use of the microarray technology has allowed the...*23rd May, 2007
Institute for Experimental Oncology, Oncotest GmbH, Freiburg, Germany.- Oncology. 2006;71(1-2):86-94. Epub 2007 Mar 8. ([DOI Direct Link](#))
- [Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro.](#)
*Mistletoe extracts are widely used in complementary and alternative cancer...*30th March, 2007
Oncotest GmbH, Institute for Experimental Oncology, Am Flughafen 12, 79018- Anticancer Res. 2007 Jan-Feb;27(1A):223-33.
- [Arugosins G and H: prenylated polyketides from the marine-derived fungus Emericellanidulans var. acristata.](#)
*The fungus Emericella nidulans var. acristata was isolated as an endophyte...*21st September, 2006
Institute for Pharmaceutical Biology, University of Bonn, Nussallee 6,- J Nat Prod. 2006 Jul;69(7):995-1000. ([DOI Direct Link](#))
- [Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe \(Viscum album L.\) extracts Iscador in vitro.](#)
*Mistletoe (Viscum album L.) extracts exhibit antitumor activity based on...*16th September, 2006
Oncotest GmbH, Institut für experimentelle Onkologie, Freiburg, Germany.- Arzneimittelforschung. 2006 Jun;56(6A):435-40.
- [In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes.](#)
*The benzyl-substituted ansa-titanocenes...*17th February, 2006
Oncotest GmbH, Institute of Experimental Oncology, Freiburg, Germany.- Anticancer Drugs. 2005 Nov;16(10):1091-8.
- [Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery.](#)
*Pluripotent cells can be grown in clonogenic assays. The tumour stem-cell...*27th May, 2004
Institute for Experimental Oncology, Oncotest GmbH, Am Flughafen 12-4,- Eur J Cancer. 2004 Apr;40(6):802-20. ([DOI Direct Link](#))
- [Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro.](#)
*Extracts of Viscum album (mistletoe) are widely used as complementary...*18th December, 2002
Institute of Experimental Oncology, Oncotest GmbH, 79108 Freiburg,- Anticancer Drugs. 2002 Apr;13(4):373-9.

Press Releases on Oncotest GmbH:

[Reportlinker Adds](#)

[Microtomes/Cryostats & Automated Stainers - Global Market Trends](#)

23rd November, 2009

Reportlinker

NEW YORK, Nov. 23
/PRNewswire/ --

Reportlinker.com announces that a new market research report is available in its catalogue.

Microtomes/Cryostats & Automated Stainers - Global Market Trends [http:](#)

Reportlinker Adds Fluoroscopy and Mobile C-Arms - Global Market Opportunities	23rd November, 2009	Reportlinker	NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Fluoroscopy and Mobile C-Arms - Global Market Opportunities http://www
Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide,
Reportlinker Adds Stethoscopes - A Worldwide Market Intelligence Report	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Stethoscopes - A Worldwide Market Intelligence Report http://www
Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals's siRNA Drugs In Multiple Fully Enrolled Clinical Trials	19th November, 2009	Quark Pharmaceuticals, Inc.	-- Pfizer Inc., which licenses PF-4523655 from Quark, has completed enrollment in a Phase 2 study of PF-4523655 in patients with diabetic macular edema (DME). PF-4523655 is

BioNews Results for Oncotest GmbH



- [High Voltage Crack Detection And Visual Inspection On One Machine Platform](#)
Pharma Live: Nov 15 2009 9:16AM Matching: gmbh
- [BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antib](#)
PharmiWeb: Nov 15 2009 3:26AM Matching: gmbh
- [GM to move European headquarters to Germany](#)
Research & Development: Nov 14 2009 1:52PM Matching: gmbh
- [BioInvent, Daiichi in Antibody Pact](#)
Contract Pharma: Nov 14 2009 10:25PM Matching: gmbh

- [TET Systems signs license agreement with Novo Nordisk](#)
TradingMarkets: Nov 13 2009 7:26PM Matching: gmbh
- [K2M to Enter German Spine Marketplace](#)
Freshnews.com: Nov 13 2009 12:29AM Matching: gmbh
- [BASF announces new brand: Polyurethane Solutions](#)
Chemie.de: Nov 13 2009 7:05PM Matching: gmbh
- [TET Systems and Novo Nordisk sign license agreement](#)
b3c Newswire: Nov 13 2009 5:44PM Matching: gmbh
- [BioInvent Signs Licensing Agreement with Daiichi Sankyo Co Ltd. for the Discovery and Development of Therapeut](#)
BioSpace: Nov 13 2009 3:44PM Matching: gmbh
- [BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antib](#)
Pharma Live: Nov 13 2009 2:51PM Matching: gmbh
- [BioInvent International, Daiichi Sankyo sign licence and discovery agreement](#)
News-Medical.Net: Nov 13 2009 1:41PM Matching: gmbh
- [Nuvo Research, Ranbaxy signs deal to market Oxoferin in Asian countries](#)
PharmaBiz: Nov 13 2009 12:12PM Matching: gmbh
- [BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antibodies](#)
Centre Daily Times: Nov 13 2009 11:44AM Matching: gmbh
- [BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antibodies](#)
NewsBlaze: Nov 13 2009 10:55AM Matching: gmbh
- [BioInvent Signs Licensing Agreement with Daiichi Sankyo for the Discovery and Development of Therapeutic Antib](#)
Genetic Engineering News: Nov 13 2009 8:17AM Matching: gmbh

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

